Table 2 A summary of CAR-T cells redirected against different antigens for the treatment of patients with solid tumors
From: Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Clinical trial identifier | Antigen | Indication | Estimated enrollment | Start date | Estimated Completion Date | Source | Conditioning regimen | Phase | Location |
|---|---|---|---|---|---|---|---|---|---|
NCT03373097 | GD2 | Neuroblastoma | 42 | January 5, 2018 | December 2027 | Autologous | – | I/II | Italy |
NCT02744287 | PSCA | Pancreatic cancer, prostate cancer | 151 | November 2016 | February 2024 | – | – | I/II | US |
NCT03941626 | DR5 | Hepatoma | 50 | September 1, 2019 | December 1, 2021 | Autologous | Flu/Cy | I/II | China |
NCT04429451 | PSMA | Various solid tumors | 100 | January 1, 2020 | December 31, 2024 | Autologous | – | I/II | China |
NCT02541370 | CD133 | Advanced solid tumors | 20 | June 2015 | June 2019 | Autologous | – | I/II | China |
NCT04107142 | NKG2DL | R/R solid tumor | 10 | December 1, 2019 | March 1, 2021 | Allogeneic | – | I | Malaysia |
NCT03874897 | Claudin18.2 | Advanced solid tumor | 50 | March 26, 2019 | March 20, 2022 | Autologous | Flu/Cy | I | China |
NCT02442297 | HER2 | Brain tumor | 28 | February 2016 | January 2036 | Autologous | – | I | US |
NCT04153799 | EGFR | Non-small cell lung cancer | 11 | November 1, 2019 | December 2022 | Autologous | – | I | China |
NCT04214392 | MMP2 (Matrix Metallopeptidase 2) | Glioblastoma | 36 | February 26, 2020 | February 6, 2023 | Autologous | – | I | US |
NCT02905188 | Glypican 3 | Hepatocellular carcinoma | 14 | March 28, 2019 | October 2036 | Autologous | Flu/Cy | I | US |
NCT04003649 | IL-13Rα2 | R/R glioblastoma | 60 | September 26, 2019 | December 1, 2022 | Autologous | – | I | US |
NCT03851146 | Lewis Y | Advanced solid tumors | 21 | November 24, 2016 | December 31, 2024 | Autologous | Flu/Cy | I | Australia |
NCT04025216 | TnMUC1 | Advanced solid tumors | 112 | October 10, 2019 | October 31, 2036 | Autologous | Flu/Cy | I | US |
NCT04185038 | B7-H3 | Central nervous system tumor | 70 | December 11, 2019 | May 2041 | Autologous | – | I | US |
NCT02915445 | EpCAM | Nasopharyngeal carcinoma and breast cancer | 30 | July 2016 | July 2022 | Autologous | Cy | I | China |
NCT02706392 | ROR1 | Non-small cell lung cancer and breast cancer | 60 | March 16, 2016 | December 1, 2036 | Autologous | Flu/Cy | I | US |
NCT04020575 | cleaved form of MUC1 (MUC1*) | Breast cancer | 69 | January 15, 2020 | January 15, 2035 | Autologous | – | I | US |
NCT04513431 | CEA | Colorectal cancer | 18 | August 30, 2020 | August 30, 2023 | – | –– | Early I | China |
NCT03323944 | Mesothelin | Pancreatic cancer | 18 | September 15, 2017 | September 2021 | – | Cy | I | US |
NCT03993743 | CD147 | Advanced hepatocellular carcinoma | 34 | May 27, 2019 | May 27, 2022 | Autologous | – | I | China |
NCT03907527 | MUC16 | Ovarian cancer | 71 | April 30, 2019 | April 1, 2026 | Autologous | – | I | US |
NCT03283631 | EGFRvIII | Glioblastoma | 2 | May 30, 2018 | June 30, 2020 | Autologous | – | I | US |
NCT02617134 | MUC1 | Glioblastoma, gastric and colorectal cancer | 20 | November 2015 | November 2018 | Autologous | – | I/II | China |
NCT03672305 | c-Met | Hepatocellular carcinoma | 50 | October 1, 2018 | October 30, 2019 | – | – | Early I | China |
NCT01218867 | VEGFR2 | Renal cancer | 24 | November 10, 2010 | December 15, 2015 | Autologous | Flu/Cy | I/II | US |